357 related articles for article (PubMed ID: 9684808)
1. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
2. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
3. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E
Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753
[TBL] [Abstract][Full Text] [Related]
5. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.
Klement P; Borm A; Hirsh J; Maraganore J; Wilson G; Weitz J
Thromb Haemost; 1992 Jul; 68(1):64-8. PubMed ID: 1514174
[TBL] [Abstract][Full Text] [Related]
6. Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
White HD; Ellis CJ; French JK; Aylward P
Aust N Z J Med; 1998 Aug; 28(4):551-4. PubMed ID: 9777138
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
[TBL] [Abstract][Full Text] [Related]
8. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
9. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
10. Direct thrombin inhibitors as adjuncts to thrombolytic therapy.
French JK; White HD
Curr Cardiol Rep; 1999 Sep; 1(3):184-91. PubMed ID: 10980840
[TBL] [Abstract][Full Text] [Related]
11. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
White HD
Am J Cardiol; 1998 Oct; 82(8B):57P-62P. PubMed ID: 9809893
[TBL] [Abstract][Full Text] [Related]
13. Hirudin: clinical potential of a thrombin inhibitor.
Johnson PH
Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
[TBL] [Abstract][Full Text] [Related]
14. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Haskel EJ; Prager NA; Sobel BE; Abendschein DR
Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
[TBL] [Abstract][Full Text] [Related]
15. Hirudin and hirudin analogues as new anticoagulant agents.
Pineo GF; Hull RD
Curr Opin Hematol; 1995 Sep; 2(5):380-5. PubMed ID: 9372023
[TBL] [Abstract][Full Text] [Related]
16. Hirudin and Hirulog.
White H
Aust N Z J Med; 1993 Dec; 23(6):769-70. PubMed ID: 8141724
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
White HD; Aylward PE; Frey MJ; Adgey AA; Nair R; Hillis WS; Shalev Y; Brown MA; French JK; Collins R; Maraganore J; Adelman B
Circulation; 1997 Oct; 96(7):2155-61. PubMed ID: 9337184
[TBL] [Abstract][Full Text] [Related]
18. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
Liu JT; Paul W; Emerson M; Cicala C; Page CP
Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
[TBL] [Abstract][Full Text] [Related]
19. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
20. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.
Lidón RM; Théroux P; Lespérance J; Adelman B; Bonan R; Duval D; Lévesque J
Circulation; 1994 Apr; 89(4):1567-72. PubMed ID: 8149522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
